We review the available information about the prevalence of SLFN11 in ovarian cancer, the possibilities of its determination in tumor tissue, as well as the current level of evidence about the correlation between SLFN11 expression levels in ovarian cancer and response to DDA or PARPi. This evidence concerns the gene SLFN11 and neoplasm.